Skip to content
Biopharma EHS Podcast Episode No. 16 episode artwork

May 14, 2011 31 min

Biopharma EHS Podcast Episode No. 16

from Biopharma EHS

In this podcast, Dean M. Calhoun, CIH and Joe Nieusma, Ph.D. of Affygility Solutions discuss Category 4 and Category 5 Potent Compounds - Understanding the Risks. Items covered include: Review of the last podcast What factors go into determining an active pharmaceutical ingredients as a Category 4 or Category 5 potent compound We provide examples of Category 4 and Category 5 potent compounds Review upcoming events and happenings related to environmental, health and safety in the biotechnology, pharmaceutical, and medical device industry. If you have any questions please contact Affygility Solutions at 303-884-3028 or visit the Affygility Solutions website.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Biopharma EHS Podcast Episode No. 16

0:00 31:07

No transcript yet.

Requests help us decide what to transcribe next.

BioCentury This Week BioCentury BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem. Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere Jesús E. Moreno Hosted by Jesús E. Moreno (Business Development Director, bioaccess®), Global Trial Accelerators™ is a clinical trials podcast for life-sciences founders and innovators in MedTech, Biotech/Biopharma, and Radiopharma, focused on first-in-human (FIH) and early feasibility studies. The show is produced by bioaccess® and was founded by Co-Founder & CEO Julio G. Martinez-Clark. bioaccess® is a CRO purpose-built for first-in-human (FIH) trials, serving MedTech, Biopharma, and Radiopharma startups. This podcast delivers strategies, regulatory insights, and founder stories to get your technology into humans faster and affordably, with data designed to support FDA and EMA submissions. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and founders who have compressed timelines, reduced costs, and generated the clinical evidence investors demand by drawing on on-demand clinical research capability across the Americas. What You Business Of Biotech Ben Comer The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect. BioBoss John Simboli BioBoss is a podcast about leadership in the biopharma community. Hear directly from the founders and CEOs of today's most innovative companies. Listen in as Wyant Simboli Principal and branding veteran John Simboli poses the questions "What drives you? How do you create change? Why should people care?" to biopharma leaders and hear insights on this rapidly developing field.

Frequently asked questions

How long is this episode of Biopharma EHS?

This episode is 31 minutes long.

When was this Biopharma EHS episode published?

This episode was published on May 14, 2011.

Can I download this Biopharma EHS episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.